PREEMPTIVE THERAPY VERSUS UNIVERSAL PROPHYLAXIS WITH VALGANCICLOVIR IN MINIMIZING THE RISK OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS

被引：0
|
作者：
Khan, Muhammad [1 ]
机构：
[1] DOW Univ Hosp, Karachi, Pakistan
来源：
TRANSPLANT INTERNATIONAL | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
MP077
引用
收藏
页码：295 / 295
页数：1
相关论文
共 50 条
  • [31] Effect of Cytomegalovirus Infection on Survival of Older Kidney Transplant Patients (D plus /R plus ): Impact of Valganciclovir Prophylaxis Versus Preemptive Therapy
    Luna, E.
    Caravaca, F.
    Ferreira, F.
    Fernandez, N.
    Martin, P.
    Vargas, M. L.
    Vargas, M. L.
    Saenz de Santamaria, J.
    Garcia Pino, G.
    Azevedo, L.
    Munoz Sanz, A.
    TRANSPLANTATION PROCEEDINGS, 2016, 48 (09) : 2931 - 2937
  • [32] Efficacy and safety of valganciclovir in prophylaxis of cytomegalovirus disease in renal transplant recipients.
    Gabardi, S
    Powelson, J
    Baroletti, SA
    Cina, JL
    Goggins, WC
    PHARMACOTHERAPY, 2003, 23 (03): : 412 - 413
  • [33] Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients
    Khoury, J. A.
    Storcha, G. A.
    Bohl, D. L.
    Schuessler, R. M.
    Torrence, S. M.
    Lockwood, M.
    Gaudreault-Keener, M.
    Koch, M. J.
    Miller, B. W.
    Hardinger, K. L.
    Schnitzler, M. A.
    Brennan, D. C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (09) : 2134 - 2143
  • [34] Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients
    Lopez-Medrano, F.
    Rueda, B.
    Lizasoain, M.
    Juan, R. San
    Folgueira, D.
    Andres, A.
    Morales, J. M.
    Jimenez, C.
    Meneu, J. C.
    Aguado, J. M.
    TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (05) : 400 - 404
  • [35] Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients
    Luan, F. L.
    Chopra, P.
    Park, J.
    Norman, S.
    Cibrik, D.
    Ojo, A.
    TRANSPLANTATION PROCEEDINGS, 2006, 38 (10) : 3673 - 3675
  • [36] Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients
    Vila, A
    Guirado, LL
    Balius, A
    Díaz, M
    Baró, E
    Olaya, M
    Andrade, M
    Agraz, I
    Solá, R
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (06) : 2335 - 2336
  • [37] The Cost-effectiveness of Valganciclovir Prophylaxis Versus Preemptive Therapy in CMV R+ Kidney Transplant Recipients Over the First Year Posttransplantation
    Villeneuve, Claire
    Rerolle, Jean-Phillipe
    Couzi, Lionel
    Westeel, Pierre-Francois
    Etienne, Isabelle
    Esposito, Laure
    Kamar, Nassim
    Buchler, Mathias
    Thierry, Antoine
    Marquet, Pierre
    Monchaud, Caroline
    TRANSPLANTATION DIRECT, 2024, 10 (08):
  • [38] Universal Prophylaxis with Oral Valganciclovir Significantly Reduces First Year CMV Disease in Kidney Transplant Recipients
    Wu, M. -J.
    Tu, P. -T.
    TRANSPLANTATION, 2012, 94 (10) : 531 - 531
  • [39] Expanded valganciclovir prophylaxis in kidney transplant recipients is associated with lower incidence of cytomegalovirus infection
    Veceric-Haler, Zeljka
    Bizjak, Bostjan
    Romozi, Karmen
    Arnol, Miha
    CLINICAL NEPHROLOGY, 2017, 88 : S126 - S130
  • [40] EXTENDING VALGANCICLOVIR PROPHYLAXIS IN KIDNEY TRANSPLANT RECIPIENTS IS ASSOCIATED WITH LOWER INCIDENCE OF CYTOMEGALOVIRUS INFECTION
    Bizjak, Bostjan
    Veceric-Haler, Zeljka
    Romozi, Karmen
    Arnol, Miha
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 407 - 407
12345